Highest-materiality recent filing
Concentra repurchases 1M shares from Chairman at $34.65/share for $34.65M
Repurchased 1,000,000 shares from Chairman Robert A. Ortenzio and related trusts at $34.65/share, total $34.65M.
Concentra Q2 revenue up 10%, net income up 46%; raises FY guidance; CEO succession to DiCanio
Q2 revenue $606M (+10% YoY), net income $67.3M (+45.7%), adjusted EBITDA $140.9M (+22.5%).
Concentra CMO Dr. John Anderson to retire; enters consulting agreement with equity vesting terms
Dr. John R. Anderson, EVP and CMO, retires Dec 31, 2026; consulting agreement Jan 1-Dec 31, 2027.
Concentra Q1 revenue $569.6M (+13.7%); raises FY26 guidance; declares $0.0625 dividend
Revenue $569.6M (+13.7% YoY); net income $52.3M (+28.7%); EPS $0.39, adjusted EPS $0.40.
Concentra stockholders elect directors, approve say-on-pay and auditor ratification
Elected Vipin Gopal, William K. Newton, and Dr. Marc R. Watkins as Class II directors with 98%+ 'For' votes (excluding broker non-votes).
Concentra CMO Dr. John Anderson to retire Dec 31, 2026; consulting role planned
Dr. John Anderson, EVP and Chief Medical Officer, will retire effective December 31, 2026.
Concentra Q4 revenue +15.9% to $539M; guides FY2026 rev $2.25B-$2.35B
Q4 2025 net income $36.2M (+58.7% YoY); EPS $0.27, adjusted EPS $0.28.
Concentra beats 2025 guidance; Q4 revenue +15.9% to $539M, FY revenue +13.9% to $2.16B
Q4 2025 revenue $539.1M (+15.9%), net income $36.2M (+58.7%), adjusted EBITDA $95.3M (+22.9%).
Concentra releases preliminary Q4 2025 operational metrics; details not provided in filing
Company published a presentation with preliminary unaudited Q4 2025 operational metrics.
Concentra grants 645,000 restricted shares to six named executive officers; vest over four years
CEO W. Keith Newton received 225,000 restricted shares; CFO Matthew T. DiCanio received 180,000 shares.
Concentra Q3 revenue +17% to $572.8M, EPS $0.38, raises FY2025 guidance
Revenue $572.8M (+17% YoY); net income $49.8M; EPS $0.38; adjusted EPS $0.39.
Concentra Q2 revenue $550.8M (+15.2%), raises FY 2025 guidance
Q2 revenue $550.8M (+15.2% YoY), net income $46.2M, EPS $0.35, adjusted EPS $0.37.
Concentra appoints Vipin Gopal and Brigid Bonner to board, effective July 1, 2025
Vipin Gopal and Brigid Bonner appointed to Concentra board, effective July 1, 2025.
Concentra closes $55M acquisition of Pivot Onsite Innovations, doubling onsite clinics to ~350
Acquired all equity of Onsite Innovations (Pivot Onsite) for $55M, using cash and revolver.
Concentra Q1 revenue $500.8M (+7.1% YoY), Adj. EBITDA $102.7M (+6.8%), raises 2025 guidance
Net income $40.6M ($0.30 EPS); adjusted EPS $0.32, down from $0.49 YoY due to higher interest from IPO recap.
Concentra shareholders elect two Class I directors and approve say-on-pay at 2025 annual meeting
Daniel J. Thomas elected with 112,356,457 votes for; Cheryl B. Pegus elected with 113,994,041 votes for.
Concentra to acquire Pivot Onsite Innovations for $55M; doubles onsite health segment
$55M acquisition of Pivot Onsite Innovations from Athletico Physical Therapy.
Q4 revenue $465.0M (+5.5% YoY); net income $22.8M ($0.17 EPS).
Concentra to acquire Nova Medical Centers for $265M; Q4 revenue $465M (+5.5% YoY)
Agreement to buy all membership interests of Nova Medical Centers for $265M; expected close in Q1 2025.
Concentra approves 2025 base salaries for named executive officers
CEO William K. Newton 2025 base salary set at $850,000.
Concentra grants 585K restricted shares to 5 named executive officers
CEO W. Keith Newton receives 225,000 shares; vests equally over 4 years.
Concentra completes spin-off from Select Medical; distributes 104M shares to Select stockholders
Select Medical distributed 104,093,503 shares of Concentra common stock (81.7% ownership) to its stockholders.
Concentra furnishes investor presentation; content not disclosed in filing text
Regulation FD disclosure of a presentation for Q4 2024 investor discussions.
Concentra Q3 revenue $489.6M (+3.3%); Adj. EBITDA $101.6M; declares $0.0625 dividend
Net income $45.8M, EPS $0.37; Adjusted EBITDA margin 20.7% vs 20.9% YoY.
Concentra amends CFO DiCanio's employment: salary to $550K, severance extended to 18 months
Base salary increased to $550,000, effective January 1, 2024.
Concentra completes IPO, enters $1.25B credit facility and issues $650M notes
Completed IPO of 22.5M shares at $23.50/share, net proceeds ~$499.7M.
Concentra Q2 revenue up 2.3% to $477.9M; completed IPO on July 26
Net income $53.1M (-1.8% YoY); EPS $0.50 (-2.0% YoY); Adjusted EPS $0.49.
Dr. John R. Anderson notified Concentra Group Holdings Parent, Inc. (the “Company”) of his retirement from his position as Executive Vice President and Chief Medical Officer of the Company effective as of December 31, 2026.
Max materiality 0.85 · Median 0.65 · Most common event earnings